Longitudinal Predictive Validity of the DSM-5 Anxious Distress Specifier for Clinical Outcomes in a Large Cohort of Patients With Major Depressive Disorder

2016 ◽  
Vol 78 (02) ◽  
pp. 207-213 ◽  
Author(s):  
Roxanne Gaspersz ◽  
Femke Lamers ◽  
Justine M. Kent ◽  
Aartjan T. F. Beekman ◽  
Johannes H. Smit ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Clinical Outcomes ◽  
Predictive Validity ◽  
Large Cohort ◽  
Major Depressive ◽  
Dsm 5

Comparing Effectiveness of a Combined Herbal Drug Based on Echium Amoenum with Citalopram in the Treatment of Major Depressive Disorder

2019 ◽  
Vol 16 (2) ◽  
pp. 232-238 ◽  
Author(s):  
Majid Anushiravani ◽  
Ali A. Manteghi ◽  
Ali Taghipur ◽  
Mahdi Eslami
Keyword(s):  
Randomized Controlled Trial ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Controlled Trial ◽  
Herbal Drug ◽  
Medical Sciences ◽  
Major Depressive ◽  
Dsm 5 ◽  
Randomized Controlled ◽  
Echium Amoenum

Background: According to new studies, only 60% of depressed patients respond to pharmaceutical treatment while suffering from their side effects. Natural products as adjuvant or alternative therapies should be examined to find safer and more effective ways to cope with depression. Objective: To find out the potential benefits of a combined herbal drug based on Echium amoenum compared with citalopram in the treatment of Major Depressive Disorder. Design and Setting: In psychiatry clinics of Mashhad University of Medical Sciences, 50 patients who met the criteria for Major Depressive Disorder based on DSM-5 were studied in a parallel randomized controlled trial. Design and Setting: In psychiatry clinics of Mashhad University of Medical Sciences, 50 patients who met the criteria for Major Depressive Disorder based on DSM-5 were studied in a parallel randomized controlled trial. Intervention: Subjects were randomly assigned to receive Echium amoenum compound syrup (EACS) or citalopram tablet for 8 weeks. Outcome Measures: The efficacy of treatments and recurrence of disease were surveyed and compared according to Hamilton depression rating scale at weeks 0, 4, 8, 12. Results: Patients in both groups of citalopram and EACS showed remarkable reduction in scores of Hamilton questionnaire. At the eighth week of treatment, the mean scores in EACS group were significantly lower than citalopram group (p-value = 0.03). 52% of patients suffered from various complications in citalopram group while just 12% of patients in EACS group reported few complications. Conclusion: Clinical efficacy of this herbal drug was significantly higher than citalopram, and complications were also less and lower in EACS group. Further studies with larger groups and para-clinical assessments such as serologic tests and QEEG would improve our understanding of the impacts and mechanisms of EACS.

scholarly journals Comparison of clinical outcomes with two Transcranial Magnetic Stimulation treatment protocols for major depressive disorder

2021 ◽  
Vol 14 (1) ◽  
pp. 173-180
Author(s):  
LindaL. Carpenter ◽  
ScottT. Aaronson ◽  
Todd M. Hutton ◽  
Miriam Mina ◽  
Kenneth Pages ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Transcranial Magnetic Stimulation ◽  
Depressive Disorder ◽  
Clinical Outcomes ◽  
Magnetic Stimulation ◽  
Major Depressive ◽  
Treatment Protocols

Measures of the DSM–5 mixed-features specifier of major depressive disorder

CNS Spectrums ◽  
2017 ◽  
Vol 22 (2) ◽  
pp. 196-202 ◽  
Author(s):  
Mark Zimmerman
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Antidepressant Medication ◽  
Reliability And Validity ◽  
Mixed States ◽  
Major Depressive ◽  
Manic Symptoms ◽  
Dsm 5 ◽  
Depressed Patients ◽  
Mixed Features

During the past two decades, a number of studies have found that depressed patients frequently have manic symptoms intermixed with depressive symptoms. While the frequency of mixed syndromes are more common in bipolar than in unipolar depressives, mixed states are also common in patients with major depressive disorder. The admixture of symptoms may be evident when depressed patients present for treatment, or they may emerge during ongoing treatment. In some patients, treatment with antidepressant medication might precipitate the emergence of mixed states. It would therefore be useful to systematically inquire into the presence of manic/hypomanic symptoms in depressed patients. We can anticipate that increased attention will likely be given to mixed depression because of changes in the DSM–5. In the present article, I review instruments that have been utilized to assess the presence and severity of manic symptoms and therefore could be potentially used to identify the DSM–5 mixed-features specifier in depressed patients and to evaluate the course and outcome of treatment. In choosing which measure to use, clinicians and researchers should consider whether the measure assesses both depression and mania/hypomania, assesses all or only some of the DSM–5 criteria for the mixed-features specifier, or assesses manic/hypomanic symptoms that are not part of the DSM–5 definition. Feasibility, more so than reliability and validity, will likely determine whether these measures are incorporated into routine clinical practice.

Validity of the DSM-5 anxious distress specifier for major depressive disorder

2018 ◽  
Vol 36 (1) ◽  
pp. 31-38 ◽  
Author(s):  
Mark Zimmerman ◽  
Jacob Martin ◽  
Patrick McGonigal ◽  
Lauren Harris ◽  
Sophie Kerr ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Dsm 5

scholarly journals Underlying Dimensions of DSM-5 Posttraumatic Stress Disorder and Major Depressive Disorder Symptoms

2013 ◽  
Vol 6 (4) ◽  
pp. 290-298 ◽  
Author(s):  
Tracey L. Biehn ◽  
Jon D. Elhai ◽  
Laura D. Seligman ◽  
Marijo Tamburrino ◽  
Cherie Armour ◽  
...  
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Posttraumatic Stress ◽  
Stress Disorder ◽  
Major Depressive ◽  
Dsm 5

scholarly journals Simultaneous rTMS and psychotherapy in major depressive disorder: Clinical outcomes and predictors from a large naturalistic study

2018 ◽  
Vol 11 (2) ◽  
pp. 337-345 ◽  
Author(s):  
Lana Donse ◽  
Frank Padberg ◽  
Alexander T. Sack ◽  
A. John Rush ◽  
Martijn Arns
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Clinical Outcomes ◽  
Naturalistic Study ◽  
Major Depressive

scholarly journals Anhedonia in Schizophrenia and Major Depressive Disorder Clinical and Functional MRI Study

2021 ◽  
pp. 139-154
Author(s):  
Amr Mohamad Elsarnagawy ◽  
Rasha Ahmad Elshafeay ◽  
Adel Abd-Elkarim Badawy ◽  
Ehab Sayed Ramadan ◽  
Gamal Ibrahim Shamma
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Assessment Tools ◽  
P Value ◽  
Major Depressive ◽  
Dsm 5 ◽  
Depressed Patients ◽  
Schizophrenic Patients ◽  
Group 2 ◽  
Group 1

Background: Anhedonia, is defined as reduced capacity to gain pleasure from pleasurable experiences, is a key symptom of major depression. Several studies had investigated anhedonia in schizophrenia and major depressive disorder, using different psychometric and radiological assessment tools with controversy results in either severity of anhedonia or radiological findings. The aim of this study was to differentiate the nature of the issue of anhedonia in schizophrenia versus major depressive disorder; from clinical and brain function part of view, and to study different variables in this regard. Methods: This study was carried on 60 participants who were divided into three groups: Group 1: 20 schizophrenic patients, diagnosed according to DSM-5. The symptoms of schizophrenic patients must include anhedonia as a main symptom, Group 2: 20 patients with major depressive disorder according to DSM-5 criteria, and anhedonia was one of their prominent symptoms, Group 3: 20 control subjects. Results: Our results revealed statically significant differences between participants as regards age of onset, occupational career. Statically significant differences were found between 3 groups. Most of patients in group 1 lacks the interest for social activities and intimate relationships. Statically significant Difference was found between patients in both groups compared to controls. Striatal activity (mainly caudate) was significantly diminished in group 2 (P value <0.001) and group 1 (P value 0.002) relative to controls. Prefrontal activity (ventromedial area ''vmPFC'' and dorsolateral area ''DLPFC'') was increased significantly in group 2 more than control group (P value 0.034). Group 1 shows significantly decreased activation than controls (P value 0.019).  Significant differences were found between group 1 and 2 (P value <0.001). Orbito-frontal activity was increased significantly in depressed patients more than group 1 (P <0.001) and controls (P =0.019). Conclusions: Anhedonia is a highly disabling symptom in patients with schizophrenia or MDD, associated with poor outcome. Depressed anhedonic patients have higher incidence of suicidal ideas, thoughts, and behavior. Depressed patients showed significant striatal hypoactivation associated with hyper activation of prefrontal and orbitofrontal areas. Schizophrenic patients showed diminished activation at striatal areas and frontal cortex.  We fail to find significant correlation between severity of anhedonia in both patient groups and degree of fMRI activation in different brain areas involved in reward processing.

scholarly journals Reducing Anhedonia in Major Depressive Disorder with Future Event Specificity Training (FEST): A Randomized Controlled Trial

2021 ◽  
Author(s):  
David John Hallford ◽  
Danielle Rusanov ◽  
Joseph Yeow ◽  
David W. Austin ◽  
Arnaud D'Argembeau ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Clinical Outcomes ◽  
Symptom Severity ◽  
Control Group ◽  
Clinical Effects ◽  
Future Thinking ◽  
Future Event ◽  
Global Functioning ◽  
Major Depressive

Objective: Improving future thinking may be one means to reduce anhedonia, particularly in Major Depressive Disorder (MDD) in which future thinking is impaired. The current study therefore examined whether enhancing future thinking is a viable method of reducing anhedonia in MDD. Methods: Participants (N=177; 80.8% women; M age=43.7, SD=11.8) with a current depressive episode including anhedonia and high symptom severity were randomized to a Future Event Specificity Training (FEST) program or wait-list control. Future thinking characteristics, anhedonia-related variables, and other clinical outcomes were assessed at baseline, one- and three-month follow-up. Results: The FEST group showed significantly improved future thinking characteristics compared to the control group, as expected. Relative to the control group, FEST was also associated with a reduced likelihood of anhedonia (35.1% vs 61.1%, p = .015), improvements on other anhedonia-related variables such as anticipatory (d = 0.63, p = .004) and anticipated pleasure (d = 0.77, p &lt; .001), and desirable clinical outcomes such as less people meeting criteria for MDD (37.8% vs 64.8%, p = .011), lower symptom severity (d = 0.41, p = .048), higher behavioural activation (d = 0.71, p = .001) and improved global functioning (d = 0.52, p = .017). Changes in future thinking characteristics were found to mediate the effect of FEST on anhedonia.Conclusions: Future thinking can be enhanced in MDD, and this leads to a substantially reduced likelihood of anhedonia, other significant clinical effects and functional gains. Future research might examine FEST’s effects on other diagnostic groups with anhedonia and the utility of FEST as an adjunct to other treatments.

Sign in / Sign up

Export Citation Format

Share Document